Improved Prognosis for Recurrent Epithelial Ovarian Cancer By early Diagnosis and 125I Seeds Implantation During Suboptimal Secondary Cytoreductive Surgery: A Case Report and Literature Review

Abstract

<jats:title>Abstract</jats:title> <jats:p>Background: Epithelial ovarian cancer (EOC) has the worst prognosis in all of gynecologic malignant tumors because of its high recurrence and eventually chemo-resistance. Early diagnosis of recurrence is crucial to avoid diffuse dissemination. Traditional treatment failure in recurrent ovarian cancer remains a challenge for clinicians. On the other hand, <jats:sup>125</jats:sup>I brachytherapy has been accepted as a useful treatment for multiple advanced cancers in recent years. However, its success in advanced epithelial ovarian cancer is limited. Here we report a case of recurrent ovarian cancer who had been early diagnosis of isolated recurrence and successfully treated with <jats:sup>125</jats:sup>I seeds implantation during suboptimal cytoreductive surgery.Case presentation: A 59-year-old woman presented with recurrent epithelial ovarian cancer who have had a medical history of ovarian cancer stage IIIB and an R0 resection had been achieved before presented in our hospital. She underwent suboptimal secondary cytoreductive surgery after four cycles of chemotherapy with little effectiveness and severe chemotherapy-related side effects. Approximately 70% of the cancer-bulk was resected during surgery. For residual lesion which fixed around the right ureter and right external iliac vessel, <jats:sup>125</jats:sup>I seeds implantation was performed. Postoperatively, the patient was treated with two cycles of combination chemotherapy with paclitaxel and carboplatin. The patient was free of disease at 26 months’ follow-up period. Conclusion: In recurrent EOC patients with unresectable isolated lesion, salvage <jats:sup>125</jats:sup>I seeds implantation are feasible and may contribute to survival.</jats:p>